UCHL5 [GST-tagged] Deconjugating enzyme: Deubiquitylase

Alternate Names: AD-019, CGI-70, UBL5, UCH37

Cat. No.	64-0008-050	
Lot. No.	30069	

Quantity: 50 µg Storage: -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS



CERTIFICATE OF ANALYSIS Page 1 of 2

Protein Sequence: Please see page 2

Background

Deconjugating enzymes (DCEs) are proteases that process ubiquitin or ubiquitinlike gene products, reverse the modification of proteins by a single ubiquitin or ubiquitin-like protein (UBL) and remodel polyubiquitin (or poly-UBL) chains on target proteins (Reyes-Turcu et al., 2009). The deubiguitylating – or deubiguitinating - enzymes (DUBs) represent the largest family of DCEs and regulate ubiquitin dependent signaling pathways. The activities of the DUBs include the generation of free ubiquitin from precursor molecules, the recycling of ubiquitin following substrate degradation to maintain cellular ubiquitin homeostasis and the removal of ubiquitin or ubiquitin-like proteins (UBL) modifications through chain editing to rescue proteins from proteasomal degradation or to influence cell signalling events (Komander et al., 2009). There are two main classes of DUB; cysteine proteases and metalloproteases. Ubiquitin carboxyl-terminal hydrolase L5 (UCHL5) is a member of the cysteine protease enzyme family and cloning of the human gene was first described by Wicks et al. (2005). The deubiquitylating activity of the proteasome has been attributed to the action of three deubiquitylases: UCHL5, USP14 and RPN11, which are all localised in the 19S regulatory particle. It has been reported that loss of both UCHL5 and USP14 leads to the accumulation of polyubiquitylated proteins and an inhibition of protein degradation without altering the structure or catalytic properties of the proteasome (D'Arcy et al., 2011). UCHL5 has been reported to interact with

Continued on page 2



Species: human

Source: E. coli

Quantity: 50 µg

Concentration: 0.5 mg/ml

Formulation: 50 mM HEPES pH 7.5, 150 mM sodium chloride, 2 mM dithiothreitol, 10% glycerol

Molecular Weight: ~64 kDa


Purity: >88% by InstantBlue™ SDS-PAGE

Stability/Storage: 12 months at -70°C; aliquot as required

Quality Assurance

Purity:

4-12% gradient SDS-PAGE InstantBlue™ staining Lane 1: MW markers Lane 2: 1 µg GST-UCHL5



Protein Identification:

Confirmed by mass spectrometry.

Deubiquitylase Enzyme Assay:

The activity of GST-UCHL5 was validated by determining the increase in fluorescence measured as a result of the enzyme catalysed cleavage of the fluorogenic substrate Ubiquitin-Rhodamine110-Glycine generating Ubiquitin and Rhodamine110-Glycine. Incubation of the substrate in the presence or absence of GST-UCHL5 was compared confirming the deubiquitylating activity of GST-UCHL5.

UBIQUIGENT www.ubiquigent.com Dundee, Scotland, UK

 ORDERS / SALES SUPPORT

 International:
 +1-617-245-0003

 US Toll-Free:
 1-888-4E1E2E3 (1-888-431-3233)

 Email:
 sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC) US/Canada: +1-617-245-0020 (9AM-5PM UTC) Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services. © Ubiquigent 2012. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

UCHL5 [GST-tagged] Deconjugating enzyme: Deubiquitylase

Alternate Names: AD-019, CGI-70, UBL5, UCH37

Cat. No.	64-0008-050	Quar
Lot. No.	30069	Stora
FOR RESEA	RCH USE ONLY	NOT

ntity: 50 µg -70°C age:

FOR USE IN HUMANS

Continued from page 1



CERTIFICATE OF ANALYSIS Page 2 of 2

Background

Physical Characteristics

Continued from page 1

the inhibitory protein SMAD7 by regulating transforming growth factor- β (TGF- β) receptor ubiquitylation, stability and transcription (Sacco et al., 2010). The disruption of components in the TGF-β signalling cascade is a common occurrence in human cancers (Fang et al., 2010). The activity of UCHL5 (and UCHL3) has been shown to be upregulated in the majority of tumour tissues compared to the adjacent normal tissues pointing to a specific role of these enzymes in the regulation of cell function and proliferation in different conditions, lending further support to the idea that UCHL5 (plus other deubiguitylases such as USP7 and USP9X) may constitute an interesting new target for the development of anticancer drugs (Rolen et al., 2006)

References:

D'Arcy P, Brnjic S, Olofsson MH, Fryknas M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R, Linder S (2011) Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med 17, 1636-1640.

Fang Y, Fu D, Shen XZ (2010) The potential role of ubiquitin cterminal hydrolases in oncogenesis. Biochim Biophys Acta 1806, 1-6.

Komander D, Clague MJ, Urbe S (2009) Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10, 550-563.

Reyes-Turcu FE, Ventii KH, Wilkinson KD (2009) Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Ann Rev Biochem 78, 363-397.

Rolen U, Kobzeva V, Gasparjan N, Ovaa H, Winberg G, Kissel-jov F, Masucci MG (2006) Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog 45, 260-269

Sacco JJ, Coulson JM, Clague MJ, Urbe S (2010) Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life 62, 140-157

Wicks SJ, Haros K, Maillard M, Song L, Cohen RE, Dijke PT, Chantry A (2005) The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling. Oncogene 24, 8080-8084

Protein Sequence: MSPILGYWKIKGLVQPTRLLLEYLEEKYEEH LYERDEGDKWRNKKFELGLEFPNLPYY **IDGDVKLTQSMAIIRYIADKHNMLGGCPKER** AEISMLEGAVLDIRYGVSRIAYSKDFETLKVD FLSKLPEMLKMFEDRLCHKTYLNGDHVTHP DFMLYDALDVVLYMDPMCLDAFPKLVCFK **KRIEAIPQIDKYLKSSKYIAWPLQGWQATF** GGGDHPPKSDLEVLFOGPLGSMTGNAGEW CLMESDPGVFTELIKGFGCRGAOVEEI WSLEPENFEKLKPVHGLIFLFKWQPGEEP AGSVVQDSRLDTIFFAKQVINNACATQAIVS VLLNCTHQDVHLGETLSEFKEFSQSFDAAMK GLALSNSDVIRQVHNSFARQQMFEFDTKTSA **KEEDAFHFVSYVPVNGRLYELDGLREGPIDL** GACNODDWISAVRPVIEKRIQKYSEGEIRF NLMAIVSDRKMIYEQKIAELQRQ LAEEPMDTDQGNSMLSAIQSEVAKNQM LIEEEVOKLKRYKIENIRRKHNYLPFIMELLK TLAEHQQLIPLVEKAKEKQNAKKAQETK

Tag (bold text): N-terminal GST Protease cleavage site: PreScission™ (LEVLFQ▼GP) UCHL5 (regular text): Start bold italics (amino acid residues 1-328) Accession number: AAH15521.1

Ubiquigent www.ubiquigent.com Dundee, Scotland, UK

ORDERS / SALES SUPPORT International: +1-617-245-0003

US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233) Email: sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC) US/Canada: +1-617-245-0020 (9AM-5PM UTC) Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2012. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0